A pair of deals opened up the IPO market amidst the lengthy government shutdown and delivered disappointing debuts.<\/p>\n
MapLight Therapeutics (ticker: MPLT<\/strong>) delivered a solid debut to start, selling 14.75 million shares at $17.00<\/strong> per share and opening at $19.00<\/strong>, a first-trade gain of 11.7%<\/strong>. Trading was orderly throughout the session, with shares reaching an intraday high of $20.86<\/strong> before closing near the open. Roughly 3.3 million shares<\/strong> changed hands on opening day \u2014 a notable debut that took place on a Monday<\/strong>, an uncommon start day for IPOs.<\/p>\n Despite the strong launch, the stock slipped below its $17.00<\/strong> issue price by its third trading session, dipping as low as $15.00<\/strong> before rebounding later in the week to finish Friday just under the offer level.<\/p>\n Investor feedback indicated robust participation from mutual funds and sector-focused biotech investors<\/strong>, supported by a $40 million anchor investment from T. Rowe Price<\/strong> and a Goldman Sachs\u2013led private placement<\/strong> that helped strengthen the deal\u2019s foundation.<\/p>\n Navan\u2019s IPO priced right at the midpoint of its $24\u2013$26 range<\/strong>, but the stock never came close to that level once trading began.<\/p>\n Navan (NAVN US)<\/strong> opened at $22.00<\/strong>, about 12% below its issue price<\/strong>, making it the worst-performing IPO at first trade in 2025<\/strong>. Shares continued to slide throughout the debut session, hitting an intraday low of $19.74<\/strong> (down 21%<\/strong>) before closing at $20.00<\/strong>, marking a 20% first-day decline<\/strong>\u2014the weakest debut since Metagenomi Inc. (MGX)<\/strong> dropped 31.3%<\/strong> on its first day in February 2024<\/strong>.\u00a0 The stock was considered\u00a0multiple-times oversubscribed\u00a0<\/strong>but our sources failed to provide price guidance<\/strong> –often times an ominous sign for a deal ahead of a debut.<\/p>\n The disappointing performance highlights the delicate balance between innovation premium and execution risk<\/strong> for AI-driven business models. Going forward, stability may hinge on long-term investor support, though many IPO participants tend to rotate quickly out of early underperformers. The silver lining: Navan\u2019s $922 million cash raise<\/strong> ranks among the largest IPO proceeds of 2025<\/strong>, giving the company a strong balance sheet<\/strong> and significant runway for growth. To shift sentiment, however, management will need to deliver operational traction and financial clarity<\/strong> in its first quarterly report as a public company.<\/p>\n Looking ahead to this week, five IPOs are set to price\u2014Beta Technologies Inc, <\/strong>Exzeo Group Inc., BillionToOne Inc., Grupo Aerom\u00e9xico S.A.B. de C.V., and Evommune Inc.<\/strong>\u2014with the overall deal quality taking a clear step up from this past week.<\/p>\n","protected":false},"excerpt":{"rendered":" A pair of deals opened up the IPO market amidst the lengthy government shutdown and delivered disappointing debuts. MapLight Therapeutics Inc. (MPLT): Neuroscience IPO Launches with a Bright Start, Fades Throughout First Week MapLight Therapeutics (ticker: MPLT) delivered a solid debut to start, selling 14.75 million shares at $17.00 per share and opening at $19.00,[…]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[1536],"tags":[],"class_list":["post-31889","post","type-post","status-publish","format-standard","hentry","category-subscriber-content"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/31889","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=31889"}],"version-history":[{"count":4,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/31889\/revisions"}],"predecessor-version":[{"id":31893,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/31889\/revisions\/31893"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=31889"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=31889"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=31889"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Navan Inc. (NAVN): Mispriced AI Travel Platform Stumbles in Debut<\/h2>\n